Titre : Protéine G cdc42

Protéine G cdc42 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Hyperthermic Intraperitoneal Chemotherapy
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Protéine G cdc42 : Questions médicales les plus fréquentes", "headline": "Protéine G cdc42 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Protéine G cdc42 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-21", "dateModified": "2025-02-15", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Protéine G cdc42" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Protéines G rho", "url": "https://questionsmedicales.fr/mesh/D020741", "about": { "@type": "MedicalCondition", "name": "Protéines G rho", "code": { "@type": "MedicalCode", "code": "D020741", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.338.400.700" } } }, "about": { "@type": "MedicalCondition", "name": "Protéine G cdc42", "alternateName": "cdc42 GTP-Binding Protein", "code": { "@type": "MedicalCode", "code": "D020764", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Jeong Woo Park", "url": "https://questionsmedicales.fr/author/Jeong%20Woo%20Park", "affiliation": { "@type": "Organization", "name": "Department of Biological Science, University of Ulsan, Ulsan, 44610, South Korea." } }, { "@type": "Person", "name": "Ming Huang", "url": "https://questionsmedicales.fr/author/Ming%20Huang", "affiliation": { "@type": "Organization", "name": "Environmental Toxicology Graduate Program, University of California, Riverside, Riverside, California 92521, United States." } }, { "@type": "Person", "name": "Yinsheng Wang", "url": "https://questionsmedicales.fr/author/Yinsheng%20Wang", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, University of California, Riverside, Riverside, California 92521, United States." } }, { "@type": "Person", "name": "Natsumi Maruta", "url": "https://questionsmedicales.fr/author/Natsumi%20Maruta", "affiliation": { "@type": "Organization", "name": "Plant Genetic Engineering Laboratory, School of Agriculture and Food Sciences, University of Queensland, Brisbane, QLD, 4072, Australia." } }, { "@type": "Person", "name": "Yuri Trusov", "url": "https://questionsmedicales.fr/author/Yuri%20Trusov", "affiliation": { "@type": "Organization", "name": "Plant Genetic Engineering Laboratory, School of Agriculture and Food Sciences, University of Queensland, Brisbane, QLD, 4072, Australia." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: A meta-analysis.", "datePublished": "2022-10-20", "url": "https://questionsmedicales.fr/article/36273925", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ygyno.2022.10.010" } }, { "@type": "ScholarlyArticle", "name": "Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Elderly is Safe and Effective.", "datePublished": "2022-08-05", "url": "https://questionsmedicales.fr/article/35940050", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jss.2022.06.057" } }, { "@type": "ScholarlyArticle", "name": "Study on the thermal stability of nab-paclitaxel during hyperthermic intraperitoneal chemotherapy.", "datePublished": "2023-03-01", "url": "https://questionsmedicales.fr/article/36859304", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s40360-023-00653-2" } }, { "@type": "ScholarlyArticle", "name": "Exposure to Neoadjuvant Oxaliplatin-Containing Chemotherapy, Does it Effect Intraperitoneal Hyperthermic Chemotherapy Perfusion?", "datePublished": "2022-12-09", "url": "https://questionsmedicales.fr/article/36484904", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1245/s10434-022-12933-y" } }, { "@type": "ScholarlyArticle", "name": "[Surgery of peritoneal surface malignancies - surgical cytoreduction and hyperthermic intraperitoneal chemotherapy].", "datePublished": "2023-09-12", "url": "https://questionsmedicales.fr/article/37768120", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": null } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines et peptides de signalisation intracellulaire", "item": "https://questionsmedicales.fr/mesh/D047908" }, { "@type": "ListItem", "position": 5, "name": "Protéines G", "item": "https://questionsmedicales.fr/mesh/D019204" }, { "@type": "ListItem", "position": 6, "name": "Protéines G monomériques", "item": "https://questionsmedicales.fr/mesh/D020559" }, { "@type": "ListItem", "position": 7, "name": "Protéines G rho", "item": "https://questionsmedicales.fr/mesh/D020741" }, { "@type": "ListItem", "position": 8, "name": "Protéine G cdc42", "item": "https://questionsmedicales.fr/mesh/D020764" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Protéine G cdc42 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Protéine G cdc42", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-11", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Protéine G cdc42", "description": "Comment diagnostiquer une dysfonction de cdc42 ?\nQuels tests sont utilisés pour cdc42 ?\nY a-t-il des biomarqueurs pour cdc42 ?\nQuels symptômes indiquent un problème avec cdc42 ?\nPeut-on détecter cdc42 dans des échantillons biologiques ?", "url": "https://questionsmedicales.fr/mesh/D020764?mesh_terms=Hyperthermic+Intraperitoneal+Chemotherapy&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Protéine G cdc42", "description": "Quels sont les symptômes d'une mutation de cdc42 ?\nComment cdc42 affecte-t-il la cellule ?\nY a-t-il des signes cliniques associés à cdc42 ?\nCdc42 est-il lié à des maladies spécifiques ?\nQuels effets cdc42 a-t-il sur le cytosquelette ?", "url": "https://questionsmedicales.fr/mesh/D020764?mesh_terms=Hyperthermic+Intraperitoneal+Chemotherapy&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Protéine G cdc42", "description": "Peut-on prévenir les mutations de cdc42 ?\nY a-t-il des mesures préventives pour les maladies liées à cdc42 ?\nComment le mode de vie influence-t-il cdc42 ?\nLes tests génétiques peuvent-ils prévenir des problèmes avec cdc42 ?\nY a-t-il des recommandations diététiques pour cdc42 ?", "url": "https://questionsmedicales.fr/mesh/D020764?mesh_terms=Hyperthermic+Intraperitoneal+Chemotherapy&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Protéine G cdc42", "description": "Quels traitements ciblent cdc42 ?\nPeut-on utiliser des thérapies géniques pour cdc42 ?\nY a-t-il des médicaments pour moduler cdc42 ?\nComment la recherche avance-t-elle sur cdc42 ?\nLes traitements sont-ils efficaces contre cdc42 ?", "url": "https://questionsmedicales.fr/mesh/D020764?mesh_terms=Hyperthermic+Intraperitoneal+Chemotherapy&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Protéine G cdc42", "description": "Quelles complications sont liées à cdc42 ?\nCdc42 peut-il entraîner des problèmes neurologiques ?\nY a-t-il des complications à long terme avec cdc42 ?\nComment cdc42 affecte-t-il le système immunitaire ?\nLes complications de cdc42 sont-elles réversibles ?", "url": "https://questionsmedicales.fr/mesh/D020764?mesh_terms=Hyperthermic+Intraperitoneal+Chemotherapy&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Protéine G cdc42", "description": "Quels sont les facteurs de risque pour cdc42 ?\nL'exposition à des toxines affecte-t-elle cdc42 ?\nLes antécédents familiaux augmentent-ils le risque ?\nLe stress peut-il affecter cdc42 ?\nY a-t-il des groupes à risque pour cdc42 ?", "url": "https://questionsmedicales.fr/mesh/D020764?mesh_terms=Hyperthermic+Intraperitoneal+Chemotherapy&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dysfonction de cdc42 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses de signalisation cellulaire peuvent être utilisés." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour cdc42 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests incluent l'immunoblotting et la microscopie à fluorescence." } }, { "@type": "Question", "name": "Y a-t-il des biomarqueurs pour cdc42 ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de biomarqueurs spécifiques pour cdc42." } }, { "@type": "Question", "name": "Quels symptômes indiquent un problème avec cdc42 ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des anomalies dans la migration cellulaire et la morphogenèse peuvent être observées." } }, { "@type": "Question", "name": "Peut-on détecter cdc42 dans des échantillons biologiques ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, cdc42 peut être détecté dans des échantillons de tissus ou de cellules." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une mutation de cdc42 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les mutations peuvent entraîner des troubles de la migration cellulaire et des malformations." } }, { "@type": "Question", "name": "Comment cdc42 affecte-t-il la cellule ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Cdc42 régule la forme et le mouvement des cellules, influençant leur fonction." } }, { "@type": "Question", "name": "Y a-t-il des signes cliniques associés à cdc42 ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des anomalies dans le développement et la motilité cellulaire peuvent être observées." } }, { "@type": "Question", "name": "Cdc42 est-il lié à des maladies spécifiques ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anomalies de cdc42 sont associées à des cancers et des maladies génétiques." } }, { "@type": "Question", "name": "Quels effets cdc42 a-t-il sur le cytosquelette ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Cdc42 joue un rôle clé dans la régulation du cytosquelette, influençant la forme cellulaire." } }, { "@type": "Question", "name": "Peut-on prévenir les mutations de cdc42 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention des mutations génétiques est complexe et dépend de facteurs environnementaux." } }, { "@type": "Question", "name": "Y a-t-il des mesures préventives pour les maladies liées à cdc42 ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Des conseils génétiques peuvent aider à évaluer le risque de maladies liées à cdc42." } }, { "@type": "Question", "name": "Comment le mode de vie influence-t-il cdc42 ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain peut réduire le risque de maladies associées à cdc42." } }, { "@type": "Question", "name": "Les tests génétiques peuvent-ils prévenir des problèmes avec cdc42 ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les tests génétiques peuvent identifier les porteurs de mutations de cdc42." } }, { "@type": "Question", "name": "Y a-t-il des recommandations diététiques pour cdc42 ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée peut soutenir la santé cellulaire, mais n'affecte pas directement cdc42." } }, { "@type": "Question", "name": "Quels traitements ciblent cdc42 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des inhibiteurs spécifiques de cdc42 sont en cours de développement pour le cancer." } }, { "@type": "Question", "name": "Peut-on utiliser des thérapies géniques pour cdc42 ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La thérapie génique est une approche potentielle pour corriger les mutations de cdc42." } }, { "@type": "Question", "name": "Y a-t-il des médicaments pour moduler cdc42 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des composés chimiques sont en cours d'évaluation pour moduler l'activité de cdc42." } }, { "@type": "Question", "name": "Comment la recherche avance-t-elle sur cdc42 ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "La recherche se concentre sur les inhibiteurs et les voies de signalisation associées." } }, { "@type": "Question", "name": "Les traitements sont-ils efficaces contre cdc42 ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité des traitements dépend du type de maladie et de la mutation spécifique." } }, { "@type": "Question", "name": "Quelles complications sont liées à cdc42 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des troubles du développement et des cancers." } }, { "@type": "Question", "name": "Cdc42 peut-il entraîner des problèmes neurologiques ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Des anomalies de cdc42 sont associées à des troubles neurologiques dans certains cas." } }, { "@type": "Question", "name": "Y a-t-il des complications à long terme avec cdc42 ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les complications à long terme peuvent inclure des cancers et des malformations congénitales." } }, { "@type": "Question", "name": "Comment cdc42 affecte-t-il le système immunitaire ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Cdc42 peut influencer la réponse immunitaire, mais les effets varient selon les contextes." } }, { "@type": "Question", "name": "Les complications de cdc42 sont-elles réversibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour cdc42 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des prédispositions génétiques et des influences environnementales." } }, { "@type": "Question", "name": "L'exposition à des toxines affecte-t-elle cdc42 ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines toxines environnementales peuvent influencer l'expression de cdc42." } }, { "@type": "Question", "name": "Les antécédents familiaux augmentent-ils le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de maladies génétiques peuvent augmenter le risque." } }, { "@type": "Question", "name": "Le stress peut-il affecter cdc42 ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Le stress peut influencer la signalisation cellulaire, y compris celle de cdc42." } }, { "@type": "Question", "name": "Y a-t-il des groupes à risque pour cdc42 ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Les individus avec des mutations génétiques spécifiques sont à risque accru." } } ] } ] }

Sources (10000 au total)

Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: A meta-analysis.

The value of hyperthermic intraperitoneal chemotherapy (HIPEC) at the time of cytoreductive surgery (CRS) for epithelial ovarian cancer (EOC) is controversial and its use remains experimental in most ... A comprehensive review of data from MEDLINE, EMBASE, and Cochrane Library databases was conducted from the first report on HIPEC in EOC till April 3, 2022. Progression-free survival (PFS) and overall ... Fifteen studies (10 case-control studies and 5 randomized controlled trials [RCTs]) were included in the present meta-analysis. Based on the time interval between the last systemic chemotherapy exposu... Our present meta-analysis demonstrates that the value of HIPEC at CRS for EOC appears to depend on the timing of the last systemic chemotherapy exposure. Future trials are awaited to define the role o...

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Elderly is Safe and Effective.

An increasing proportion of elderly patients (EP) are undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC). They have increased comorbidities and perioperative ri... A retrospective review of our prospectively maintained CRS/HIPEC database analyzed perioperative and oncological outcomes of EP (>70 y) compared to younger patients (YP) (<60 y).... Of 500 CRS/HIPEC patients, 62 EP and 210 YP were included. Median age was 73 y in EP and 46 y in YP. Demographic, clinical, operative, and perioperative outcomes were similar between groups. American ... Despite a significant age difference, increased comorbidities, worse American Society of Anesthesiologists, and similar Peritoneal Cancer Index burden, we found no significant differences in periopera...

Study on the thermal stability of nab-paclitaxel during hyperthermic intraperitoneal chemotherapy.

Albumin-bound paclitaxel (nab-paclitaxel), as a special targeted preparation of paclitaxel, has the advantages of good curative effect and less side effects in anti-tumor therapy. The existence of the... In this study, We examined three batches of albumin-bound paclitaxel dissolved in saline at different temperatures (25 °C, 37 °C, 41 °C, 42 °C and 43 °C) for the changes of human serum albumin content... Our results demonstrated that the indicators including human serum albumin content, human serum albumin polymer content, in-vitro release rate, paclitaxel binding rate and paclitaxel content were stab... Overall, albumin-bound paclitaxel is relatively stable to different temperatures (25 °C, 37 °C, 41 °C, 42 °C and 43 °C). This study will lay a foundation for further studies on the albumin-bound pacli...

Exposure to Neoadjuvant Oxaliplatin-Containing Chemotherapy, Does it Effect Intraperitoneal Hyperthermic Chemotherapy Perfusion?

Patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) are commonly exposed to oxaliplatin neoadjuvant chemotherapy (NAT) regimens. The impact of systemic... We conducted a retrospective review of our institutional registry of CRS/HIPEC cases who received oxaliplatin-containing NAT, and compared patients who underwent HIPEC with oxaliplatin versus cases pe... A total of 333 cases satisfied the selection criteria-159 appendiceal primaries (all high-grade disease) and 174 colorectal cases. Thirty-one cases (9.3%) underwent HIPEC with oxaliplatin, with the re... This analysis found no discernable association with NAT oxaliplatin exposure in regard to survival outcomes following CRS/HIPEC stratified out by perfusion agent....

[Surgery of peritoneal surface malignancies - surgical cytoreduction and hyperthermic intraperitoneal chemotherapy].

Peritoneal carcinosis has historically been considered as inoperable, although the technique of its resesection together with high dose intraperitoneal chemotherapy potentiated by heat has been descri...

Intraoperative metabolic changes associated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) causes considerable hemodynamic, respiratory, and metabolic changes during the perioperative period.... To evaluate metabolic changes associated with this procedure. Understanding perioperative factors and their association with morbidity may improve the perioperative management of patients undergoing t... A retrospective review of a prospectively maintained database was performed. All consecutive unselected patients who underwent CRS plus HIPEC between January 2018 and December 2020 (n = 219) were incl... The mean age was 58 ± 11.7 years and 167 (76.3%) were female. The most frequent histology diagnosis was serous ovarian carcinoma 49.3% (n = 108) and colon carcinoma 36.1% (n = 79). Mean peritoneal can... The administration of HIPEC after CRS causes significant changes in internal homeostasis. Although the closed technique causes a greater increase in temperature, it is not related to higher morbidity ...

[Surgical treatment of pseudomyxoma peritonei-Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy].

Pseudomyxoma peritonei syndrome (PMP) is an orphan disease. Surgery is the fundament of treatment.... Short review summarizing the state of the art treatment.... Cytoreductive surgery (CRS) in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) form the foundations of treatment for PMP. The peritoneal cancer index should be preoperatively determ... Standardized surgical treatment and HIPEC, optimized specific surgical training and structured follow-up at the center lead to an excellent long-term prognosis for patients with PMP....

Hyperthermic intraperitoneal chemotherapy in the treatment of recurrent ovarian cancer: When, and for whom?

The aim of this study is to evaluate the progression-free survival (PFS) of recurrent ovarian cancer (ROC) patients treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (H... ROC patients who underwent cytoreductive surgery plus HIPEC between 2015 and 2021 were retrospectively evaluated. Patients' demographic information and clinicopathological characteristics including ca... A total of 104 patients with ROC were included. The median age was 57 years and the median follow-up time was 15 months (range: 5-69 months). In Cox regression multivariate analyses, platinum resistan... HIPEC at the time of first platinum-sensitive relapse may lead to favorable PFS in the treatment ROC. However, HIPEC as salvage treatment even with R0 cytoreductive surgery does not seem effective....

Weekend Discharge Is Not Associated With Increased Readmission After Hyperthermic Intraperitoneal Chemotherapy.

We explored the association between weekend discharge and 30- and 90-d readmission rates in patients undergoing hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for peritoneal carcinomatosis.... The US HIPEC Collaborative database, comprised of a longitudinal cohort of patients undergoing CRS/HIPEC for peritoneal carcinomatosis at twelve academic institutions between 2000 and 2017, was querie... 1415 patients met inclusion criteria for the study: 1108 (78%) patients with a weekday discharge and 308 (22%) with a weekend/holiday discharge. Median age at time of surgery was 55 y (Interquartile R... Weekend discharges are safe following CRS/HIPEC. Length of stay initiatives should focus on discharging the patient when medically ready, rather than avoiding weekend discharge out of an abundance of ...

Anesthesia and pain management of pediatric cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy has shown to improve survival in patients with extensive or refractory abdominal tumors of many different histologies. Postoperativ... We present the anesthetic management and postoperative pain control strategies for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy using a multimodal, opioid-sparing, and total in... A single institution retrospective review of anesthetic management, intraoperative fluid and blood administration, and postoperative pain control for pediatric patients undergoing cytoreductive surger... We reviewed and analyzed the first 25 patient records. The most common diagnosis was desmoplastic small round cell tumor (n = 12). Median age of patients was 14 years (range 21 months-22 years). All p... Utilizing a multimodal, opioid-sparing, total intravenous anesthetic technique in conjunction with a tunneled thoracic epidural catheter, we were able to avoid the need for postoperative mechanical ve...